<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810899</url>
  </required_header>
  <id_info>
    <org_study_id>2015[969]</org_study_id>
    <secondary_id>ChiCTR-IPR-15007085</secondary_id>
    <nct_id>NCT02810899</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy</brief_title>
  <official_title>The Effect of Dexmedetomidine as an Adjuvant to General Anesthesia on Intelligence Development in Pediatric Patients Undergoing Craniotomy: a Randomized, Double-blind and Placebo-controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized, double-blind and placebo-controlled pilot study is to
      investigate whether dexmedetomidine when used as an adjuvant to general anesthesia can
      decrease the harmful effects of anesthesia and surgery on intelligence development in
      pediatric patients undergoing craniotomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      General anesthetics and sedatives are administered to millions of children each year to
      facilitate life-saving surgery and other essential surgical or medical procedures. In the
      past two decades, mounting evidence from animal and clinical studies have raised concerns
      that general anesthetics may produce harmful effects in the developing brain and lead to
      adverse neurodevelopmental outcomes. Factors that may influence the degree of injury include
      age at the time of drug exposure/surgery and cumulative anesthetic dose.

      The Intelligence Quotients of pediatric patients with intracranial tumors are lower when
      compared with healthy children of same age. The investigators suppose that these patients are
      more sensitive to the neurotoxic effects of general anesthetics. Dexmedetomidine is an alpha
      2-adrenoceptor agonist that provides sedation, anxiolysis, and analgesia, and has been shown
      to be safe to the brain in animal studies. In clinical studies, the use of dexmedetomidine
      decreases the consumption of anesthetics and opioids during general anesthesia and suppresses
      stress response induced by surgery. The investigators hypothesize that dexmedetomidine, when
      used as an adjuvant to general anesthesia, can reduce the neurotoxic effects of general
      anesthetics by decreasing anesthetic consumption and inhibiting stress response.

      The purpose of this randomized, double-blind and placebo-controlled pilot study is to
      investigate whether dexmedetomidine, when used as an adjuvant to general anesthesia, can
      decrease the harmful effects of anesthesia and surgery on intelligence development of
      pediatric patients undergoing craniotomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intelligence Quotient</measure>
    <time_frame>At 3 months after surgery</time_frame>
    <description>Tested with Chinese Binet Intelligence Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to anesthesia emergence</measure>
    <time_frame>From end of surgery until reappearance of response to oral orders, assessed up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extubation</measure>
    <time_frame>From end of surgery until extubation, assessed up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depth of sedation at the time of extubation</measure>
    <time_frame>Immediately after extubation</time_frame>
    <description>Assessed with Ramsay sedation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence agitation</measure>
    <time_frame>From end of surgery until extubation, assessed up to 24 hours</time_frame>
    <description>Agitation will be assessed with anesthesia emergence agitation score.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Length of stay in hospital after surgery</measure>
    <time_frame>From end of surgery to 30 days after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of postoperative complications</measure>
    <time_frame>From end of surgery to 30 days after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>All-cause 30-day mortality</measure>
    <time_frame>At the time of 30 days after surgery</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>All-cause 90-day mortality</measure>
    <time_frame>At the time of 90 days after surgery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Brain Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A loading dose of dexmedetomidine (0.5 ug/kg IV infusion in 15 minutes) will be administered after induction of general anesthesia, followed by continuous infusion at a rate of 0.5 ug/kg/h until the closure of the duramater of the brain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline will be administered in the same rate and volume as that in the dexmedetomidine group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.</description>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <other_name>dexmedetomidine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>0.9% sodium chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age of 2 years or older, but no more than 12 years;

          2. Plan to undergo selective craniotomy under general anesthesia for intracranial tumor
             resection;

          3. Written informed consent signed by legal guardians.

        Exclusion Criteria:

          1. Refused to participate by the legal guardians;

          2. Body weight lower than the 3rd percentile or higher than 97th percentile of the normal
             body weight reference;

          3. American Society of Anesthesiologists physical classification of IV or higher;

          4. Unable to complete preoperative intelligence assessment because of coma, dysnoesia, or
             language barrier;

          5. Diagnosed pulmonary disease (including acute respiratory tract infection) or
             cardiovascular disease (including congenital heart disease, hypertension, hypotension,
             bradycardia, atrioventricular block, or cardiac insufficiency);

          6. Abnormal liver or renal function (liver enzyme or creatinine higher than 1.5 times of
             the upper normal limit;

          7. Other congenital diseases that may affect the development of the nervous system (such
             as Down's Syndrome);

          8. Allergy to dexmedetomidine;

          9. Other conditions that are considered unsuitable for study participation by the
             attending pediatricians or investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Xin Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology and Critical Care Medicine, Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Rappaport BA, Suresh S, Hertz S, Evers AS, Orser BA. Anesthetic neurotoxicity--clinical implications of animal models. N Engl J Med. 2015 Feb 26;372(9):796-7. doi: 10.1056/NEJMp1414786.</citation>
    <PMID>25714157</PMID>
  </reference>
  <reference>
    <citation>Cattano D, Young C, Straiko MM, Olney JW. Subanesthetic doses of propofol induce neuroapoptosis in the infant mouse brain. Anesth Analg. 2008 Jun;106(6):1712-4. doi: 10.1213/ane.0b013e318172ba0a.</citation>
    <PMID>18499599</PMID>
  </reference>
  <reference>
    <citation>Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vöckler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999 Jan 1;283(5398):70-4.</citation>
    <PMID>9872743</PMID>
  </reference>
  <reference>
    <citation>Olney JW, Ishimaru MJ, Bittigau P, Ikonomidou C. Ethanol-induced apoptotic neurodegeneration in the developing brain. Apoptosis. 2000 Dec;5(6):515-21. Review.</citation>
    <PMID>11303910</PMID>
  </reference>
  <reference>
    <citation>Jevtovic-Todorovic V, Absalom AR, Blomgren K, Brambrink A, Crosby G, Culley DJ, Fiskum G, Giffard RG, Herold KF, Loepke AW, Ma D, Orser BA, Planel E, Slikker W Jr, Soriano SG, Stratmann G, Vutskits L, Xie Z, Hemmings HC Jr. Anaesthetic neurotoxicity and neuroplasticity: an expert group report and statement based on the BJA Salzburg Seminar. Br J Anaesth. 2013 Aug;111(2):143-51. doi: 10.1093/bja/aet177. Epub 2013 May 30.</citation>
    <PMID>23722106</PMID>
  </reference>
  <reference>
    <citation>Poggi G, Liscio M, Galbiati S, Adduci A, Massimino M, Gandola L, Spreafico F, Clerici CA, Fossati-Bellani F, Sommovigo M, Castelli E. Brain tumors in children and adolescents: cognitive and psychological disorders at different ages. Psychooncology. 2005 May;14(5):386-95.</citation>
    <PMID>15386759</PMID>
  </reference>
  <reference>
    <citation>Hernandez MT, Sauerwein HC, Jambaqué I, de Guise E, Lussier F, Lortie A, Dulac O, Lassonde M. Attention, memory, and behavioral adjustment in children with frontal lobe epilepsy. Epilepsy Behav. 2003 Oct;4(5):522-36.</citation>
    <PMID>14527495</PMID>
  </reference>
  <reference>
    <citation>Wang XW, Cao JB, Lv BS, Mi WD, Wang ZQ, Zhang C, Wang HL, Xu Z. Effect of perioperative dexmedetomidine on the endocrine modulators of stress response: a meta-analysis. Clin Exp Pharmacol Physiol. 2015 Aug;42(8):828-36. doi: 10.1111/1440-1681.12431.</citation>
    <PMID>26016707</PMID>
  </reference>
  <reference>
    <citation>Li Y, Wang B, Zhang LL, He SF, Hu XW, Wong GT, Zhang Y. Dexmedetomidine Combined with General Anesthesia Provides Similar Intraoperative Stress Response Reduction When Compared with a Combined General and Epidural Anesthetic Technique. Anesth Analg. 2016 Apr;122(4):1202-10. doi: 10.1213/ANE.0000000000001165.</citation>
    <PMID>26991622</PMID>
  </reference>
  <reference>
    <citation>Kim DJ, Kim SH, So KY, Jung KT. Effects of dexmedetomidine on smooth emergence from anaesthesia in elderly patients undergoing orthopaedic surgery. BMC Anesthesiol. 2015 Oct 7;15:139. doi: 10.1186/s12871-015-0127-4.</citation>
    <PMID>26446479</PMID>
  </reference>
  <reference>
    <citation>Le Bot A, Michelet D, Hilly J, Maesani M, Dilly MP, Brasher C, Mantz J, Dahmani S. Efficacy of intraoperative dexmedetomidine compared with placebo for surgery in adults: a meta-analysis of published studies. Minerva Anestesiol. 2015 Oct;81(10):1105-17. Epub 2015 May 25. Review.</citation>
    <PMID>26005187</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Xin Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>child</keyword>
  <keyword>craniotomy</keyword>
  <keyword>intelligence tests</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>Disruption</keyword>
  <keyword>Dehiscence</keyword>
  <keyword>Mild Cognitive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

